GLPG
Price:
$27.98
Market Cap:
$1.66B
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Industry
Biotechnology
IPO Date
2012-02-27
Stock Exchange
NASDAQ
Ticker
GLPG
According to Galapagos N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.53B. This represents a change of -13.77% compared to the average of 1.77B of the last 4 quarters.
The mean historical Enterprise Value of Galapagos N.V. over the last ten years is 350.60M. The current 1.53B Enterprise Value has changed 43.52% with respect to the historical average. Over the past ten years (40 quarters), GLPG's Enterprise Value was at its highest in in the September 2025 quarter at 1.89B. The Enterprise Value was at its lowest in in the September 2021 quarter at 0.
Average
350.60M
Median
0
Minimum
0
Maximum
1.75B
Discovering the peaks and valleys of Galapagos N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Enterprise Value = 1.75B
Minimum Annual Increase = 0%
Minimum Annual Enterprise Value = 0
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 1.75B | Infinity% |
| 2024 | 0 | 0% |
| 2023 | 0 | 0% |
| 2022 | 0 | 0% |
The current Enterprise Value of Galapagos N.V. (GLPG) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
584.34M
5-year avg
350.60M
10-year avg
350.60M
Galapagos N.V.’s Enterprise Value is less than argenx SE (58.84B), greater than Assembly Biosciences, Inc. (472.23M), greater than CytomX Therapeutics, Inc. (602.40M), greater than Kyntra Bio, Inc. (-21902405.00), greater than NextCure, Inc. (9.51M), less than Ultragenyx Pharmaceutical Inc. (2.51B), greater than Spero Therapeutics, Inc. (16.12M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 58.84B | $61.92B | |
| 472.23M | $502.17M | |
| 602.40M | $613.92M | |
| -21902405.00 | $28.74M | |
| 9.51M | $20.48M | |
| 2.51B | $1.43B | |
| 16.12M | $64.85M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galapagos N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Galapagos N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Galapagos N.V.'s Enterprise Value?
What is the highest Enterprise Value for Galapagos N.V. (GLPG)?
What is the 3-year average Enterprise Value for Galapagos N.V. (GLPG)?
What is the 5-year average Enterprise Value for Galapagos N.V. (GLPG)?
How does the current Enterprise Value for Galapagos N.V. (GLPG) compare to its historical average?